Vale Biolabs Secures €164K from Venture Kick to Advance AI-Powered Brain Research Platform

Vale Biolabs is building a platform that helps researchers study brain diseases and test potential treatments. The funding will support the development of this platform and help researchers better understand these conditions.

Vale Biolabs will use the funding to improve its automated research platform and develop more human brain organoid models. These models are small, lab-grown structures that help scientists study how the human brain works and understand brain diseases.

The funding will also help the company collect data to train and test its AI models. In addition, Vale Biolabs plans to work more closely with research organisations and industry partners to further develop its technology.

Vale Biolabs was founded by Ilaria Incaviglia, Angeliki Damilou, Daniel Medina Cano and Theodoulos Rodosthenous. The team brings experience in brain research, laboratory automation, data science and building early-stage companies.

The company combines lab-grown human brain tissue, automated technology and AI to help researchers understand how the brain reacts to different drugs. Its platform aims to support the development of new treatments for brain-related diseases.

Developing treatments for brain diseases is difficult. Much of the early research relies on animal testing. However, animals and humans do not always respond to drugs in the same way. This makes it harder to predict whether a treatment will work in people. As a result, some drugs fail during clinical trials, increasing development costs and delaying new treatments.

Vale Biolabs aims to solve this problem by creating small, lab-grown models of human brain tissue called brain organoids. These models copy some features of the human brain and help researchers study diseases and test potential treatments.

Read Also- Onodrim Industries Raises $300 Mn at $1.3 Bn Valuation to Expand European Defence and Industrial Businesses